Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients

NCT04732455 is registered in ClinicalTrials.gov with Gamal Mohamed Taha Abouelmagd as lead sponsor.

NCT NCT04732455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients
Lead sponsor
Gamal Mohamed Taha Abouelmagd
Phase
Not applicable
Overall status
Completed
Start date
January 15, 2021
Completion date
July 5, 2022
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, chemotherapy-induced peripheral neuropathy, peripheral neuropathy